What Schedule IV Control Means for Oveporexton

On November 12, 2026, a Drug Enforcement Administration interim final rule took effect and placed oveporexton in Schedule IV of the Controlled Substances Act. The rule is Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV, Docket No. DEA-1775, published at 91 Fed. Reg. 72775. Read the rule (PDF).

Oveporexton is the active ingredient in Orzeyful. The Food and Drug Administration approved that drug on August 5, 2026, for narcolepsy type 1 in adults. The rule gives the chemical name as N-[(2S,3R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide. The listing covers oveporexton, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.

What the rule does

An interim final rule is a rule that takes effect while comments are still open. The Department of Health and Human Services sent DEA a scheduling recommendation on July 31, 2026. DEA reviewed that evaluation and completed its own eight-factor analysis under 21 U.S.C. § 811(c). The rule says DEA concluded that oveporexton meets the Schedule IV criteria in 21 U.S.C. § 812(b)(4).

Section 812(b)(4) has three parts. The substance has a low potential for abuse relative to the substances in Schedule III. It has a currently accepted medical use in treatment in the United States. Abuse of it may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.

21 U.S.C. § 811(j) is the reason this is an interim final rule. The rule describes that subsection this way: when HHS approves a new drug and recommends control in Schedule II, III, IV, or V, DEA must issue an interim final rule within 90 days. That 90 days runs from the later of two dates: the date DEA receives the HHS recommendation, or the date DEA receives notice of the approval. The rule also says the interim final rule becomes effective immediately, without a separate good-cause finding. DEA Administrator Terrance C. Cole signed the document on November 6, 2026. The Federal Register filing line says it was filed at 4:15 p.m. on November 9, 2026. The dates section says the rule is effective November 12, 2026.

Comments are still open. They must be submitted electronically or postmarked on or before December 14, 2026. The electronic system will not accept comments after 11:59 p.m. Eastern Time that day. A request for a hearing, and a waiver of an opportunity for a hearing or to participate in a hearing, must be received on or before that same date. This document is a scheduling rule. It is not a court opinion.

The amendatory text adds oveporexton as paragraph (f)(8) of 21 C.F.R. § 1308.14, with DEA controlled-substance code 1775.

Which controls apply

The rule says oveporexton is subject to the Schedule IV regulatory controls and to the administrative, civil, and criminal sanctions that apply to manufacture, distribution, dispensing, importing, exporting, research, and instructional activities. The rule lists ten controls. The ones below are registration, security, inventory, prescriptions, import and export, and liability.

Registration. A person who handles oveporexton must be registered with DEA under 21 U.S.C. §§ 822, 823, 957, and 958, and under 21 C.F.R. parts 1301 and 1312. Handling, as the rule uses the word, includes manufacturing, distributing, reverse distributing, dispensing, importing, exporting, research, instructional activities, chemical analysis, and possession. The rule says those registration requirements do not apply to patients who possess oveporexton under a lawful prescription.

Security and inventory. Registrants must follow the Schedule III through V security rules in 21 C.F.R. §§ 1301.71 through 1301.77. A registrant must take an initial inventory and then inventory controlled substances, including oveporexton, every two years, under 21 U.S.C. § 827. The rule says the security and inventory requirements do not apply to patients who possess the drug under a lawful prescription.

Prescriptions. Prescriptions for oveporexton, or for products containing it, must comply with 21 U.S.C. § 829 and with 21 C.F.R. parts 1306 and 1311.

Import and export. All importation and exportation of oveporexton must comply with 21 U.S.C. §§ 952, 953, 957, and 958, and with 21 C.F.R. part 1312.

The rule also says manufacturing or distribution of oveporexton may be only for legitimate purposes consistent with the drug's labeling, or for research activities authorized by the Federal Food, Drug, and Cosmetic Act and the Controlled Substances Act.

On liability, the rule states: "Any activity involving oveporexton not authorized by, or in violation of, the CSA or its implementing regulations, is unlawful, and may subject the person to administrative, civil, and/or criminal sanctions." The rule does not state a term of imprisonment. Criminal penalties for unauthorized manufacture and distribution of a controlled substance are in 21 U.S.C. § 841.

The rule is also specific about what DEA and HHS found. DEA's National Forensic Laboratory Information System has not recorded an encounter with oveporexton in the United States, and FDA is not aware of diversion from research or manufacturing. In a human abuse-potential study, Drug Liking scores for oveporexton at 18 mg and 30 mg were not statistically significantly different from phentermine 75 mg. Phentermine is already in Schedule IV. DEA concluded that the abuse potential is similar to that Schedule IV stimulant, and that abuse may lead to limited physical or psychological dependence relative to Schedule III. Those findings support the schedule. The rule does not find that any particular person possessed or distributed the drug.

From my perspective

I read this as a scheduling action that takes effect on November 12, 2026. The rule does not charge anyone. It says the drug is new, that FDA approved it for narcolepsy type 1 in adults, and that DEA has not seen it in the forensic laboratory database. The criminal exposure the rule describes is unauthorized handling of the kind it lists: manufacture, distribution, dispensing, import, export, and the related activities, when the Act or its regulations do not authorize them. A patient who has a lawful prescription sits outside the registration, security, and inventory rules DEA listed.

The comment period runs through December 14, 2026, at 11:59 p.m. Eastern Time. A hearing request is due the same day. Until a later rule changes the listing, the November 12 text is the control that applies. The place to read it is the Federal Register.